Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094258 | 0.76 | MAPT (0.38) | SLC6A4SLC6A2 | |
| SCHEMBL4097077 | 0.75 | SLC6A4 (0.35) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL349206 | 0.73 | OPRM1 (0.44) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2994923 | 0.72 | MAPT (0.40) | SLC6A4SLC6A2 | |
| SCHEMBL29101215 | 0.70 | SLC6A3 (0.34) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7467433 | 0.70 | OPRL1 (0.39) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4441268 | 0.69 | SLC6A2 (0.43) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1557061 | 0.68 | OPRM1 (0.43) | — | |
| SCHEMBL4093386 | 0.67 | HSD11B1 (0.42) | — | |
| SCHEMBL4106029 | 0.67 | HSD11B1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | SLC6A4 704/4885SLC6A3 491/4885SLC6A2 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.